In vitro susceptibility testing in Aspergillus species: An update

Future Microbiology

Volumn 5, Issue 5, 2010, Pages 789-799

  Lass Flrl, Cornelia ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Aspergillus; In vitro antifungal susceptibility testing; In vitro resistance; In vivo resistance

Indexed keywords

2,3 BIS(2 METHOXY 4 NITRO 5 DULFOPHENYL) 5 [(PHENYLAMINO)CARBONYL] 2H TETRAZOLIUM HYDROXIDE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; ERGOSTEROL; FLUCONAZOLE; FLUORESCENT DYE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; POSACONAZOLE; RAVUCONAZOLE; TETRAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VORICONAZOLE;

AGAR DIFFUSION; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ASPERGILLOSIS; ASPERGILLUS; ASPERGILLUS FUMIGATUS; ASSAY; BROTH DILUTION; COLORIMETRY; CONCENTRATION RESPONSE; CROSS RESISTANCE; DISK DIFFUSION; DRUG POTENTIATION; EPSILOMETER TEST; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FUNGICIDAL ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; INVASIVE ASPERGILLOSIS; LIPOGENESIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; REVIEW;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; HUMANS; MICROBIAL SENSITIVITY TESTS;

ASPERGILLUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS TERREUS; EMERICELLA NIDULANS;

EID: 77952355177     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.10.34     Document Type: Review

References (119)

1. Denning DW: Therapeutic outcome in invasive aspergillosis. Clin. Infect. Dis. 23, 608-615 (1996).
2. Bodey GP, Vartivarian S: Aspergillosis. Eur. J. Clin. Microbiol. Infect. Dis. 8, 413-437 (1989). (Pubitemid 19142009)
3. Herbrecht R, Denning D, Patterson TF et al.: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347, 408-415 (2002). (Pubitemid 34851833)
4. Maertens J, Boogaerts M: Caspofungin in the treatment of candidosis and aspergillosis. Int. J. Infect. Dis. 7, 94-101 (2003). (Pubitemid 36753513)
5. Bodey GP, Bueltmann B, Duguid W et al.: Fungal infections in cancer patients: an international autopsy study. Eur. J. Clin. Microbiol. Infect. Dis. 11, 99-109 (1992).
6. Walsh T, Annaissie E, Dennind DW et al.: Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46, 327-360 (2009). (Pubitemid 351265310)
7. Lass-Flörl C, Griff K, Mayr A et al.: Epidemiology and outcome of infections due to Aspergillus terreus: 10?year single centre experience. Br. J. Haematol. 131, 201-207 (2005). (Pubitemid 43899686)
8. Kontoyiannis DP, Lewis RE: Antifungal drug resistance of pathogenic fungi. Lancet 359, 1135-1144 (2002). (Pubitemid 34270742)
9. Samson R, Varga J: What is a species in Aspergillus? Med. Mycol. 47, S13-S20 (2009).
10. Balajee S, Gribskov J, Hanley E, Nickle D, Marr K: Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus. Eukaryot. Cell 4, 625-632 (2005). (Pubitemid 40383765)
11. Espinel-Ingroff A: Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). J. Clin. Microbiol. 41, 403-409 (2003). (Pubitemid 36098607)
12. Espinel-Ingroff A, Bartlett M, Bowden R et al.: A multicenter evaluation of the standardization of antifungal susceptibility testing for flamentous fungi. J. Clin. Microbiol. 35, 139-143 (2004).
13. Moore BC, Sayers N, Mosquera J, Slaven J, Denning DW: Antifungal drug resistance in Aspergillus. J. Infect. 41, 203-220 (2000). (Pubitemid 32051038)
14. Rex JH, Pfaller M, Rinaldi MG, Polak A, Galgani NJ: Antifungal susceptibility testing. Clin. Microbiol. Rev. 6, 367-381 (1993). (Pubitemid 23306592)
15. Rodriguez-Tudela JL, Chryssanthou E, Petrikkou E, Mosquera J, Dennind DW, Cuenza?Estrella M: Interlaboratory evaluation of hematocytometer method of inoculum preparation for testing antifungal susceptibilities of flamentous fungi. J. Clin. Microbiol. 41, 5236-5237 (2003). (Pubitemid 37429948)
16. Clinical Laboratory Standard Institute: Reference method for broth dilution antifungal susceptibility testing of flamentous fungi. Approved standard. M38?A2. Clinical Laboratory Standard Institute, Wayne, PA, USA (2008).
17. Lass-Florl C, Cuenca-Estrella M, Denning D, Rodriguez-Tudela J: Antifungal susceptibility testing in Aspergillus spp. according to EUCAST methodology. Med. Mycol. 44 (Suppl. 1), 319-325 (2006). (Pubitemid 44524124)
18. Lass-Florl C, Perkhofer S: In vitro susceptibility testing in Aspergillus species. Mycoses 51, 437-446 (2008).
19. Verweij P, Howard DH, Melchers WJG, Denning D: Azole resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist. Updat. 12, 141-147 (2009).
20. Neofytos D, Horn D, Anaissie E et al.: Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: ana lysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin. Infect. Dis. 48, 265-273 (2009).
21. Baddley JW, Marr KA, Andes DR et al.: Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant?Associated Infection Surveillance Network (TRANSNET). J. Clin. Microbiol. 47, 3271-3275 (2009).
22. Pfaller M, Diekema DJ, Ghannoum A et al.: Wild type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute Broth Microdilution Methods. J. Clin. Microbiol. 47, 3142-3146 (2009).
23. Gehrt A, Peter J, Pizzo P, Walsh T: Effect of increasing inoculum sizes of pathogenic flamentous fungi on MICs of antifungal agents by broth microdilution method. J. Clin. Microbiol. 33, 1302-1307 (1995).
24. Meletiadis J, Meis J, Mouton J, Verweij PE: Analysis of growth characteristics of flamnetous fungi in different nutrient media. J. Clin. Microbiol. 39, 478-484 (2001). (Pubitemid 32150804)
25. Gomez-Lopez A, Aberkane A, Petrikkou E, Mellado E, Rodriguez-Tudela JL: Analysis of the infuence of tween concentration, inoculum size, assay medium, and reading time on susceptibility testing of Aspergillus spp. J. Clin. Microbiol. 43, 1251-1255 (2005). (Pubitemid 40364947)
26. Aberkane A, Cuenca-Estrella M, Gomez-Lopez A et al.: Comparative evaluation of two different methods of inoculum preparation for antifungal susceptibility testing of filamentous fungi. J. Antimicrob. Chemother. 50, 719-722 (2002). (Pubitemid 35331690)
27. Petrikkou E, Rodriguez-Tudela JL, Cuenca-Estrella M, Gomez A, Molleja A, Mellado E: Inoculum standardization for antifungal susceptibility testing of flamentous fungi pathogenic for humans. J. Clin. Microbiol. 39, 1345-1347 (2001). (Pubitemid 32275433)
28. Espinel-Ingroff A: History of medical mycology in the United States. Clin. Microbiol. Rev. 9, 235-272 (1996). (Pubitemid 26124458)
29. Denning DW, Venkateswarlu K, Oakley KL et al.: Itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 41, 1364-1368 (1997). (Pubitemid 27231443)
30. Jahn B, Stuben A, Bhakdi S: Colorimetric susceptibility testing for Aspergillus fumigatus: comparison of menadione-augmented 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide and Alamar blue tests. J. Clin. Microbiol. 34, 2039-2041 (1996). (Pubitemid 26239252)
31. Lionakis M, Russell R, Torres H, Albert N, Raad I, Kontoyiannis D: Increased frequency of non-fumigatus Aspergillus species in amphotericin B-or triazole-pre-exposed cancer patients with positive cultures for aspergilli. Diagn. Microbiol. Infect. Dis. 52, 15-20 (2005). (Pubitemid 40692735)
32. Kitahara M, Seth V, Medoff G, Kobayashi G: Antimicrobial susceptibility testing of six clinical isolates of Aspergillus. Antimicrob. Agents Chemother. 9, 908-914 (1976).
33. Kartsonis N, Nielsen J, Douglas C: Caspofungin: the frst in a new class of antifungal agents. Drug Resist. Updat. 6, 197-218 (2003). (Pubitemid 37129919)
34. Kurtz M, Heath I, Marrinan J, Dreikorn S, Onishi J, Douglas C: Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1, 3)-β-dglucan synthase. Antimicrob. Agents Chemother. 38, 1480-1489 (1994). (Pubitemid 24203556)
35. Arikan S, Lozano-Chiu M, Paetznick V, Rex J: In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob. Agents Chemother. 45, 327-330 (2001). (Pubitemid 32039139)
36. Odds F, Motyl M, Andrade R et al.: Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J. Clin. Microbiol. 42, 3475-3482 (2004). (Pubitemid 39045669)
37. Espinel-Ingroff A: Utility of mould susceptbility testing. Curr. Opin. Infect. Dis. 16, 527-532 (2003).
38. Rex J, Pfaller M: Has antifungal susceptibility testing come of age? Clin. Infect. Dis. 35, 982-989 (2002). (Pubitemid 35178316)
39. Arenderup M, Perkhofer S, Howard SJ et al.: Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. Antimicrob. Agents Chemother. 52, 3504-3511 (2008).
40. Dannaoui E, Borel E, Monier M, Piens M, Picot S, Persat F: Acquired itraconazole resistance in Aspergillus fumigatus. J. Antimicrob. Chemother. 47, 333-340 (2001). (Pubitemid 32229575)
41. Denning DW, Radford SA, Oakley KL, Hall L, Johnson EM, Warnock DW: Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J. Antimicrob. Chemother. 40, 401-414 (1997). (Pubitemid 27437961)
42. Oakley KL, Morrissey G, Denning DW: Effcacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole- susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob. Agents Chemother. 41, 1504-1507 (1997). (Pubitemid 27289676)
43. van der Linden J, Jansen R, Bresters D et al.: Azole-resistant central nervous system aspergillosis. Clin. Infect. Dis. 48, 1111-1113 (2009).
44. Snelders E, van der Lee H, Kuijper J et al.: Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 5, e219 (2009).
45. Verweij PE, Mellado E, Melchers WJG: Multiple-triazole-resistant aspergillosis. N. Engl. J. Med. 356, 1481-1483 (2007).
46. Howard S, Webster I, Moore BC et al.: Multi-azole resistance in Aspergillus fumigatus. Int. J. Antimicrob. Agents 28, 450-453 (2006). (Pubitemid 44740492)
47. Hodiamont C, Dolman K, Ten Berge I, Melchers W, Verweij P, Pajkrt D: Multipleazole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery. Med. Mycol. 47, 217-220 (2009).
48. Dannaoui E, Persat F, Monier M, Borel E, Piens M, Picot S: In-vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole. J. Antimicrob. Chemother. 44, 553-555 (1999). (Pubitemid 29490629)
49. Alcazar-Fuoli L, Mellado E, Alastruey-Izquiderdo A, Cuenca-Estrella M, Rodriguez-Tudela JL: Species identifcation and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. Antimicrob. Agents Chemother. 53, 4514-4517 (2009).
50. Lass-Flörl C, Kofer G, Kropshofer G et al.: In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J. Antimicrob. Chemother. 42, 497-502 (1998). (Pubitemid 28473010)
51. Hara KS, Ryu JH, Lie JT, Roberts GD: Disseminated Aspergillus terreus infection in immunocompromised hosts. Mayo Clin. Proceed. 64, 770-775 (1989).
52. Iwen PC, Rupp ME, langnas AN, Reed EC, Hinrichs SH: Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-years experience and review of the literature. Clin. Infect. Dis. 26, 1092-1097 (1998).
53. Steinbach W, Benjamin D, Kontoyiannis D et al.: Infections due to Aspergillus terreus: a multicenter retrospective ana lysis of 83 cases. Clin. Infect. Dis. 39, 192-198 (2004). (Pubitemid 38971489)
54. Walsh T, Petraitis V, Petraitiene R et al.: Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J. Infect. Dis. 188, 305-319 (2003). (Pubitemid 36898165)
55. Warn PA, Morrissey G, Morrissey J, Denning DW: Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B. J. Antimicrob. Chemother. 51, 913-919 (2003). (Pubitemid 36503424)
56. Ruchel R, Perske C, Glass B, Basecke J: A case of pulmonary aspergillosis with lack of response to caspofungin. Rev. Iberoam. Micol. 23, 94-96 (2006). (Pubitemid 44133527)
57. Lass-Flörl C, Perkhofer S, Mayr A: In vitro susceptibility tesing in fungi: a global perspective on a variety of methods. Mycoses 53 (1), 1-11 (2010).
58. Lass-Flörl C, Alastruey-Izquiderdo A, Cuenca-Estrella M, Perkhofer S, Rodriguez-Tudela JL: In vitro activities of various antifungal drugs against Aspergillus terreus: global assessment using the methodology of the European committee on antimicrobial susceptibility testing. Antimicrob. Agents Chemother. 53, 794-795 (2009).
59. Rodriguez-Tudela JL, Alcazar-Fuoli L, Alastruey-Izquiderdo A, Monzon A, Mellado E, Cuenca-Estrella M: Time of incubation for antifungal susceptibility testing of Aspergillus fumigatus: can MIC values be obtained at 24 hours? Antimicrob. Agents Chemother. 51, 4502-4504 (2007). (Pubitemid 350209914)
60. Espinel-Ingroff A, Dawson K, Pfaller M et al.: Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for flamentous fungi. Antimicrob. Agents Chemother. 39, 314-319 (1995).
61. Warn PA, Sharp A, Guinea J, Denning DW: Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Aspergillus and Candida. J. Antimicrob. Chemother. 53, 743-749 (2004). (Pubitemid 38660273)
62. Pfaller M, Boyken L, Hollis RJ et al.: In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method. J. Clin. Microbiol. 47, 3323-3325 (2009).
63. Espinel-Ingroff A, Fothergill A, Ghannoum M et al.: Quality control and reference guidlines for CLSI broth microdilution susceptibility testing (M38-A document) of anidulafungin against moulds. J. Clin. Microbiol. 45, 2180-2182 (2007). (Pubitemid 47203790)
64. Fuller J, Schoefld A, Jiwa S, Sand C, Jansen B, Rennie R: Caspofungin Etest endpoint for Aspergillus isolates shows poor agreement with the reference minimum effective concentration. J. Clin. Microbiol. 48, 479-482 (2010).
65. Odabasi Z, Paetznick V, Rex JH, Ostrosky-Zeichner L: Effects of serum on in vitro susceptibility testing of echinocandins. Antimicrob. Agents Chemother. 51, 4214-4216 (2007). (Pubitemid 350057834)
66. Rex J, Pfaller M, Walsh T et al.: Antifungal susceptibility testing: practical aspects and current challenges. Clin. Microbiol. Rev. 14, 643-658 (2001). (Pubitemid 32979625)
67. Pfaller M, Messer SA, Mills K, Bolmstrom A: In vitro susceptibility testing of flamentous fungi: comparison of Etest and reference microdilution methods for determining itraconazole MICs. J. Clin. Microbiol. 38, 3359-3361 (2000). (Pubitemid 36555673)
68. Szekely A, Johnson E, Warnock D: Comparison of E-test and broth microdilution methods for antifungal drug susceptibility testing of moulds. J. Clin. Microbiol. 37, 1480-1483 (1999). (Pubitemid 29187822)
69. Meletiadis J, Mouton J, Meis J, Bouman B, Verweij PE: Comparison of the Etest and the Sensititre Colorimetric methods with the NCCLS proposed standard for antifungal susceptibility testing of Aspergillus species. J. Clin. Microbiol. 40, 2876-2885 (2002). (Pubitemid 35284956)
70. Martin-Mazuelos E, Peman J, Valverde A, Chaves M, Serrano MC, Canton E: Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp J. Antimicrob. Chemother. 52, 365-370 (2003). (Pubitemid 37120713)
71. Guinea J, Pelaez T, Recio S, Torres-Narbona M, Bouza E: In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fuconazole against 1, 007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob. Agents Chemother. 52, 1396-1400 (2008). (Pubitemid 351522004)
72. Therese K, Bagyalakshmi R, Madhavan N, Deepa P: In-vitro susceptibility testing by agar dilution method to determine the minimum inhibitory concentrations of amphotericin B, fuconazole and ketoconazole against ocular fungal isolates. Indian J. Med. Microbiol. 24, 273-279 (2007). (Pubitemid 46033979)
73. Espinel-Ingroff A, Arthington-Skaggs BA, Igbal N et al.: A multicenter evaluation of a new disk agar diffusion method for susceptibility testing of flamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin-B and caspofungin. J. Clin. Microbiol. 45, 1811-1820 (2007). (Pubitemid 46933912)
74. Messer SA, Diekema DJ, Hollis RJ et al.: Evaluation of disk diffusion and Etest compared with broth microdilution for antifungal susceptibility testing of posaconazole against clinical isolates of flamentous fungi. J. Clin. Microbiol. 45, 1322-1324 (2007). (Pubitemid 46626507)
75. Espinel-Ingroff A: Comparison of three commercial assays and a modifed disk diffusion assay with two broth microdilution reference assays for testing zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B. J. Clin. Microbiol. 44, 3616-3622 (2006). (Pubitemid 46768814)
76. Ozkutuk A, Ergon C, Metin D, Yucesoy M, Polat S: Comparison of disk diffusion, E-test and broth microdilution test in determination of susceptibility of Aspergillus species to amphotericin B, itraconazole and voriconazole. J. Chemother. 20, 87-92 (2008). (Pubitemid 351428668)
77. Arendrup M, Garcia-Effron G, Buzina W et al.: Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrob. Agents Chemother. 53, 1185-1193 (2009).
78. Guinea J, Pelaez T, Alcala L, Bouza E: Correlation between the E test and the CLSI M-38 A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus. Diagn. Microbiol. Infect. Dis. 56, 53-55 (2006). (Pubitemid 44279940)
79. Carrillo-Muñoz A, Quindos G, Ruesqa M et al.: In vitro antifungal susceptibility testing of flamentous fungi with Sensititre Yeast One. Mycoses 49, 293-297 (2006). (Pubitemid 43894052)
80. Castro C, Serrano MC, Flores B, Espinel-Ingroff A, Martin-Mazuelos E: Comparison of the Sensititre YeastOne colorimetric antifungal panel with a modifed NCCLS M38-A method to determine the activity of voriconazole against clinical isolates of Aspergillus spp. J. Clin. Microbiol. 42, 4358-4360 (2004). (Pubitemid 39296177)
81. Meletiadis J, Meis JFGM, Mouton JW, Donnelly JP, Verweij PE: Comparison of NCCLS and 3-(4, 5-dimethyl-2-thiazyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of flamentous fungi and development of a new simplifed method. J. Clin. Microbiol. 38, 2949-2954 (2000). (Pubitemid 30640579)
82. Te Dorsthorst DTA, Zwaaftink RB, Rijs A, Meletiadis J, Verweij PE: A colorimetric and spectrophotometric method for in vitro susceptibility testing of Aspergillus species against caspofungin. Med. Mycol. 45, 351-355 (2007). (Pubitemid 46839804)
83. Antachopoulos C, Meletiadis J, Sein T, Roilides E, Walsh T: Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species. Antimicrob. Agents Chemother. 51, 881-887 (2007). (Pubitemid 46355271)
84. Sande WV, Tavakol M, Vianen WV, Bakker-Woudenberg I: The effects of antifungal agents to conidial and hyphal forms of Aspergillus fumigatus. Med. Mycol. 18, 1-8 (2009).
85. Mowat E, Butcher J, Lang S, Williams C, Ramage G: Development of a simple model for studying the effects of antifungal agents on multicellular communities of Aspergillus fumigatus. J. Med. Microbiol. 56, 1205-1212 (2007). (Pubitemid 47477193)
86. Vale-Silvia L, Buchta V: Antifungal susceptibility testing by fow cytometry: is it the future? Mycoses 49, 261-273 (2006). (Pubitemid 43894048)
87. Ramani R, Angwar M, Haturvedi V: Flow cytometry antifungal susceptibility testing of Aspergillus fumigatus and comparison of mode of action of voriconazole vis-a-vis amphotericin B and itraconazole. Antimicrob. Agents Chemother. 47, 3627-3629 (2003). (Pubitemid 37345734)
88. Balajee SA, Marr KA: Conidial vability assay for rapid susceptibility testing of Aspergillus species. J. Clin. Microbiol. 40, 2741-2745 (2002).
89. Lass-Flörl C, Nagl M, Speth C, Ulmer H, Dierich MP, Würzner R: Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining. Antimicrob. Agents Chemother. 45, 124-128 (2001). (Pubitemid 32039103)
90. Arthington-Skaggs BA, Jradi H, Desai T, Morrison CJ: Quantitation of ergosterol content: novel method for determination of fuconazole susceptibility of Candida albicans. J. Clin. Microbiol. 37, 3332-3337 (1999). (Pubitemid 29455229)
91. Blum G, Perkhofer S, Haas H et al.: Potential basis for amphotericin B resistance in Aspergillus terreus. Antimicrob. Agents Chemother. 52, 1553-1555 (2008). (Pubitemid 351522034)
92. Araujo R, Coutinho I, Espinel-Ingroff A: Rapid method for testing the susceptibility of Aspergillus fumigatus to amphotericin B, itraconazole, voriconazole and posaconazole by assessment of oxygen consumption. J. Antimicrob. Chemother. 62, 1277-1280 (2008).
93. Steinbach W, Stevens D, Dennind DW: Combination and sequential therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1996 to 2001. Clin. Infect. Dis. 37, S188-S224 (2003). (Pubitemid 37260462)
94. Meletiadis J, Pournaras S, Roilides E, Walsh T: Defning fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation ana lysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus. Antimicrob. Agents Chemother. 54, 602-609 (2010).
95. Johnson M, MacDougall C, Ostrosky-Zeichner L, Perfect J, Rex J: Combination antifungal therapy. Antimicrob. Agents Chemother. 48, 693-715 (2004). (Pubitemid 38280314)
96. Perkhofer S, Lugger H, Dierich MP, Lass-Florl C: Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro. Antimicrob. Agents Chemother. 51, 791-793 (2007). (Pubitemid 46185310)
97. Perkhofer S, Jost D, Dierich MP, Lass-Flörl C: Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions. Antimicrob. Agents Chemother. 52, 1873-1875 (2008). (Pubitemid 351614693)
98. Kiraz N, Dag I, Yamac M, Kiremitci A, Kasifoglu N, Akgun Y: Antifungal activity of caspofungin in combination with amphotericin B against Candida glabrata: comparison of disk diffusion, Etest, and time-kill methods. Antimicrob. Agents Chemother. 53, 788-790 (2009).
99. Rodriguez-Tudela J, Cazar-Fuoli L, Mellado E, Astruey-Izquierdo A, Monzon A, Cuenca-Estrella M: Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob. Agents Chemother. 52, 2468-2472 (2008). (Pubitemid 351915677)
100. Xiao L, Madison V, Chau A, Loebenberg D, Palermo R, McNicholas P: Threedimensional models of wild-type and mutated forms of cytochrome P450 14α-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob. Agents Chemother. 48, 568-574 (2004). (Pubitemid 38141718)
101. Liu W, Lionakis M, Lewis R, Wiederhold N, May G, Kontoyiannis D: Attenuation of itraconazole fungicidal activity following preexposure of Aspergillus fumigatus to fuconazole. Antimicrob. Agents Chemother. 47, 3592-3597 (2003). (Pubitemid 37345725)
102. Mosquera J, Denning DW: Azole crossresistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 46, 556-557 (2002). (Pubitemid 34087215)
103. Mellado E, Garcia-Effron G, Buitrago MJ, Cazar-Fuoli L, Cuenca-Estrella M, Rodriguez-Tudela JL: Targeted gene disruption of the 14-α sterol demethylase (cyp51A) in Aspergillus fumigatus and its role in azole drug susceptibility. Antimicrob. Agents Chemother. 49, 2536-2538 (2005). (Pubitemid 40734499)
104. Warris A, Weemaes C, Verweij PE: Multidrug resistance in Aspergillus fumigatus. N. Engl. J. Med. 347, 2173-2174 (2002).
105. Pfaller MA, Messer SA, Boyken L et al.: In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J. Clin. Microbiol. 46, 2568-2572 (2008).
106. Pavie J, Lacroix C, Hermoso D et al.: Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis. J. Clin. Microbiol. 43, 4902-4904 (2005). (Pubitemid 41298308)
107. Weiler S, Lass-Flörl C, Auberger J, Bellmann-Weiler R, Stein M, Joannidis M: Triazole-resistant candidaemia following posaconazole exposure. Int. J. Antimicrob. Agents 33, 494-495 (2008).
108. Auberger J, Lass-Flörl C, Clausen J et al.: First case of breakthrough pulmonary Aspergillus niveus infection in a patient after allogeneic hematopoietic stem cell transplantation. Diagn. Microbiol. Infect. Dis. 62, 336-339 (2008).
109. Monk BC, Goffeau A: Outwitting multidrug resistance to antifungals. Science 321, 367-369 (2008). (Pubitemid 352035829)
110. Belete B, Raberin H, Morel J, Flori P, Hafd J, Sung R: Acquired resistance to voriconazole and itraconazole in a patient with pulmonary aspergilloma. Med. Mycol. 19, 1-4 (2009).
111. Alcazar-Fuoli L, Rodriguez-Tudela J, Mellado E: Antifungal drug resistance in molds: clinical and microbiological factors. Curr. Fung. Infect. Rep. 2, 36-42 (2008).
112. Gulshan K, Moye-Rowley W: Multidrug resistance in fungi. Eukaryot. Cell 6, 1933-1942 (2007). (Pubitemid 350221262)
113. Denning D, Radford SA, Oakley KL, Hall L, Johnson E, Warnock D: Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J. Antimicrob. Agents 40, 401-414 (1997). (Pubitemid 27437961)
114. Espinel-Ingroff A, Fothergill A, Peter J, Rinaldi MG, Walsh TJ: Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS Collaborative Study. J. Clin. Microbiol. 40, 3204-3208 (2002). (Pubitemid 34977429)
115. Espinel-Ingroff A, Chaturvedi V, Fothergill A, Rinaldi MG: Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study. J. Clin. Microbiol. 40, 3776-3781 (2002). (Pubitemid 34977429)
116. Pfaller M, Sheehan D, Rex J: Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. Clin. Microbiol. Rev. 17, 268-280 (2004). (Pubitemid 38534030)
117. Peterson L, Shanholtzer C: Tests for bactericidal effects of antimicrobial agents: technical performance and clinical relevance. Clin. Microbiol. Rev. 5, 420-432 (1992).
118. Johnson EM, Oakley KL, Radford SA et al.: Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. J. Antimicrob. Chemother. 45, 85-93 (2000).
119. Meletiadis J, Antachopoulos C, Stergiopoulou T, Pournaras S, Roilides E, Walsh TJ: Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology. Antimicrob. Agents Chemother. 51, 3329-3337 (2007). (Pubitemid 350067548)